Thank you for the question.
As you are aware, the minister has made her intention known that we will be publishing drug summaries moving forward, as well as making the full reports available upon request. We are trying to provide information that is meaningful to the people who are requesting and looking for that information. The drug summaries, for example—because as you've noted, the reports themselves are very, very dense and technical—will provide very, very plain language information that will be available to everyone, and particularly consumers, so they have a very good understanding of what the implications of using that drug may be, and of course they will then be able to discuss that with their practitioner.
On the other hand, in the consultations we've been doing with all of our stakeholders, we do know there are other groups, academics, for example, that are very, very interested in seeing the more fulsome reports of our safety assessments. We are committed to making those public. Of course we have to be mindful of potential information that we may need to redact, but really our goal is to make those as public as possible, with minimal oversight in terms of what would be removed from those reports.